257 related articles for article (PubMed ID: 26879158)
1. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.
Varadi K; Tangada S; Loeschberger M; Montsch P; Schrenk G; Ewenstein B; Turecek PL
Haemophilia; 2016 Jul; 22(4):615-24. PubMed ID: 26879158
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
3. Utilizing Plasma Composition Data to Help Determine Procoagulant Dynamics in Patients with Thermal Injury: A Computational Assessment.
Bravo MC; Tejiram S; McLawhorn MM; Moffatt LT; Orfeo T; Jett-Tilton M; Pusateri AE; Shupp JW; Brummel-Ziedins KE
Mil Med; 2019 Mar; 184(Suppl 1):392-399. PubMed ID: 30901410
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E
J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555
[TBL] [Abstract][Full Text] [Related]
5. FEIBA: mode of action.
Turecek PL; Váradi K; Gritsch H; Schwarz HP
Haemophilia; 2004 Sep; 10 Suppl 2():3-9. PubMed ID: 15385040
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
Chelle P; Montmartin A; Damien P; Piot M; Cournil M; Lienhart A; Genre-Volot F; Chambost H; Morin C; Tardy-Poncet B
Haemophilia; 2019 Mar; 25(2):343-348. PubMed ID: 30690836
[TBL] [Abstract][Full Text] [Related]
7. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
8. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
[TBL] [Abstract][Full Text] [Related]
9. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
Choi Q; Kim JE; Hyun J; Han KS; Kim HK
Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659
[TBL] [Abstract][Full Text] [Related]
10. Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.
Mancuso ME; Chantarangkul V; Clerici M; Fasulo MR; Padovan L; Scalambrino E; Peyvandi F; Tripodi A; Santagostino E
Haemophilia; 2016 Jul; 22(4):e292-300. PubMed ID: 27197961
[TBL] [Abstract][Full Text] [Related]
11. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Martinowitz U; Livnat T; Zivelin A; Kenet G
Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
[TBL] [Abstract][Full Text] [Related]
12. Effects of FEIBA on platelet and leucocyte activation in severe haemophilia patients with inhibitors.
Zhao L; Uhr E; Kershaw G; Dunkley S
Platelets; 2012; 23(8):633-7. PubMed ID: 22309048
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Thrombin Generation with 4-Factor Prothrombin Complex Concentrates in Neonatal Plasma After Cardiopulmonary Bypass.
Franklin SW; Szlam F; Fernandez JD; Leong T; Tanaka KA; Guzzetta NA
Anesth Analg; 2016 Apr; 122(4):935-42. PubMed ID: 26599794
[TBL] [Abstract][Full Text] [Related]
14. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors.
Livnat T; Budnik I; Levy-Mendelovich S; Avishai E; Misgav M; Barg AA; Lubetsky A; Brutman-Barazani T; Kenet G
Blood Cells Mol Dis; 2017 Jul; 66():1-5. PubMed ID: 28689155
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the bioavailability of FEIBA with a thrombin generation assay.
Váradi K; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP; Turecek PL
J Thromb Haemost; 2003 Nov; 1(11):2374-80. PubMed ID: 14629472
[TBL] [Abstract][Full Text] [Related]
16. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.
Parmar N; Berry LR; Paredes N; Chan AK
Clin Lab; 2005; 51(3-4):157-66. PubMed ID: 15819171
[TBL] [Abstract][Full Text] [Related]
17. The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A.
Mancuso ME; Chantarangkul V; Clerici M; Fasulo MR; Padovan L; Scalambrino E; Peyvandi F; Tripodi A; Santagostino E
Haemophilia; 2016 Jul; 22(4):e286-91. PubMed ID: 27166132
[TBL] [Abstract][Full Text] [Related]
18. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.
Ettingshausen CE; Kreuz W
Haemophilia; 2010 Jan; 16(1):90-100. PubMed ID: 19878335
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab promotes factor Xa generation on endothelial cells.
Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
Hansson KM; Lindblom A; Elg M; Lövgren A
Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
